different cells and tissues. For example, 1950 circRNAs were detected in HEK293 cells and human leukocytes, 4 whereas >25,000 circular transcripts were reported in fibroblasts, 3 and meanwhile 7122 human circRNAs were annotated using data sets generated by the ENCODE project. 8 circRNAs are also formed from the well-studied transcript ANRIL, a noncoding transcript of the 9q21 locus that is associated with the risk for atherosclerosis. 9 However, little is known about the expressional regulation and the biological function of circRNAs. Recent studies suggest that cytoplasmic circRNAs may act by binding and trapping microRNAs, 4 ,10 whereas nuclear circRNAs may regulate expression and splicing of host genes. 6 Here, we characterized the expression and hypoxia-induced regulation of circRNAs in endothelial cells and showed that the circRNA cZNF292 is regulated by hypoxia in endothelial cells and controls angiogenic sprouting.
Methods
Endothelial cells were purchased from Lonza and cultured as previously described 11 under hypoxic (0.2% O 2 ) or normoxic conditions. RNA was isolated using Qiazol and miRNeasy Kits, including additional DNase I digestion. For next generation sequencing, 0.5-μg ribosomal RNA-depleted RNA was fragmented and primed. The sequencing libraries were constructed using Illumina TruSeq RNA Sample Preparation Kits and were sequenced by Illumina HiSeq 2000 flowcell. RNA-seq data were analyzed using circBase. 4, 12 To annotate the identified circRNAs, HOMER was used.
CircRNAs were validated by semiquantitative reverse transcription polymerase chain reaction (RT-PCR) using the KOD Xtreme HotStart Polymerase Kit. For RNase R digestion, 6-µg RNA was incubated with 6 U RNase R in 1× RNase R buffer in a 20-µL reaction volume at 37°C for 10 minutes followed by heat inactivation at 95°C for 3 minutes.
Angiogenesis and proliferation assays were performed after transfection with GeneTransII or RNAiMAX as described. 11 An extended method section is available in the Online Data Supplement.
Results

Identification and Characterization of Endothelial circRNAs
Endothelial circRNAs were identified in ribosomal RNAdepleted RNA of human umbilical vein endothelial cells (HUVEC) by using PYTHON scripts provided by circBase. 12 Bowtie2, 13 a short read aligner which is used to align reads
Nonstandard Abbreviations and Acronyms
CircRNA circular RNA miRNA/miR microRNA PCR polymerase chain reaction poly-A polyadenylated Figure 1 . Identification of circular RNAs (circRNAs) in endothelial cells. A, Bioinformatics pipeline for the identification of circRNAs using next generation sequencing sequence reads of rRNA-depleted RNA of human umbilical vein endothelial cells (HUVEC). Gene expression was determined from mapped reads using Cufflinks, whereas circRNAs were identified from unmapped reads using Bowtie2 in search for back-splice junction reads, according to the circBase scripts, followed by filtering of low-quality candidates, thereby excluding mitochondrial circRNAs and unique reads <2. Mapping quality of both sequence reads forming the back-splice site had to be >35 bp, whereas distance between them had to be <100 000 bp. B, Highest expressed circRNA transcripts of the 7388 total identified circRNAs in HUVEC. Data are mean+SD. C, Scatter plot of circRNA to host gene expression (selection circRNA>0, host genes<4000 fragments per kilobase of transcript per million mapped reads [FPKM] ).
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from a deep-sequencing experiment to a reference genome was used to select and analyze splice junction reads followed by filtering out low-quality candidates ( Figure 1A ). The highest expressed transcripts are shown in Figure 1B . Among the 7388 identified circRNAs of our study, we identified several new circRNAs, which are not deposited in circBase (eg, cSIRT1, cFN1, and cTGFB1; Online Table I ). The majority of the circRNAs (95.6%) derive from the gene body, whereas 1.6% are of intergenic origin and 0.5% derive from noncoding sequences (Online Table II ). Interestingly, circRNA expression did not correlate with the expression of the host genes suggesting an independent regulation of transcription versus circRNA formation ( Figure 1C ). On the basis of basal expression levels estimated using RNA-seq data and the number of reads covering the backsplice sites, we selected 8 circRNAs for further characterization. Reads of 5 selected circRNAs were derived from exon-exon back-splicing events, whereas 2 circRNAs showed back-splicing of exons to intronic sequences or intron-intron head to tail joining (Online Table III ). To confirm the expression of these circular transcripts, we performed semiquantitative reverse transcription PCR (RT-PCR) experiments using primers encompassing the circRNA-specific backsplice sites (Online Figure I ) and showed that all 8 selected candidates are expressed in HUVEC (Figure 2A ) as well as in microvascular and aortic ECs (Online Figure II) . Next, we determined whether the selected transcripts are indeed circRNAs by testing their enrichment in poly-A-negative fractions (as circRNAs are expected to have no poly-A tail 8 ) and resistance to 3′-5′ exoribonuclease RNase R digestion (as circRNAs are expected to be resistant to exonuclease RNase R 14 ) . We demonstrate that 7 of 8 circRNAs are predominantly detected in the poly-A-negative fraction ( Figure  2B and 2C), whereas the protein-coding mRNA for endothelial NO synthase was enriched in the poly-A-positive fraction ( Figure 2B and 2C). Only cMED13L was also detected Figure 2 . Confirmation and characterization of selected circular RNAs (circRNAs) in human umbilical vein endothelial cells (HUVEC). A, Expression of 8 selected circRNAs was validated by semiquantitative reverse transcription polymerase chain reaction (RT-PCR) using primers encompassing the newly formed circRNA-specific back-splice site. cANRIL was used as control. B, RNA was fractionated using oligo-dT beads followed by RT-PCR for circRNAs. Endothelial nitric oxide synthase (eNOS) mRNA was used as polyadenylated positive control. C, Quantification of fractionated poly-A+/−RNA by RT-PCR (n=3). D, Quantification of circRNAs after RNase R digestion by RT-PCR (n=3). E, Total RNA was digested using RNase R followed by RT-PCR for circRNAs. Vascular endothelial growth factor A (VEGF-A) mRNA was used as RNase-sensitive control. F, Expression of circRNAs in cytoplasmic and nuclear fractions. Malat1 was used as a positive control for nuclear localization, RPLP0 as positive control for cytoplasmic localization. All data are n=3; mean+SEM. *P<0.05. Figure 2B ). Furthermore, we show that all 8 transcripts are resistant to RNase R, whereas linear vascular endothelial growth factor-A mRNA is degraded ( Figure 2D and 2E) . Notably, all circRNAs except cMED13L were enriched in the cytoplasmic fraction, whereas the nuclear long noncoding RNA MALAT1 is detected in the nuclear fraction ( Figure 2F ). In summary, 7 of the 8 selected circRNAs fulfilled all criteria of bona fide cytoplasmic circRNAs.
Identification of Hypoxia-Regulated circRNAs
Because hypoxia is a key stimulus for angiogenesis, we next exposed HUVECs to hypoxia and determined the expression of circRNAs. Interestingly, hypoxia induced a significant regulation of circRNAs as depicted by the heat map ( Figure 3A ) and the bar graph of selected circRNAs ( Figure  3B ). The regulation of selected circRNAs by hypoxia and the hypoxia mimic CoCl 2 was subsequently validated by reverse transcription PCR (Figure 3C and 3D; Online Figure  IIIA) . In this context, cZNF292, cAFF1, and cDENND4C are upregulated, whereas cTHSD1 is reduced by hypoxia. cSRSF4 is only upregulated by 1.2-fold ( Figure 3C and 3D). PCR against cFOXJ3 yielded multiple bands excluding its analysis. With the exception of cAFF1, the regulation of circRNAs by hypoxia was even more pronounced when cells were cultured under dense conditions (Online Figure IIIB) . To determine whether the observed regulation of circRNAs is because of transcriptional regulation of host genes, host gene expression was analyzed from RNAseq data ( Figure 3E ) and validated by quantitative reverse transcription PCR ( Figure 3F ). A correlation of host gene expression and circRNA formation under hypoxia was observed for cZNF292, cDENNDA4C, and cTHSD1, whereas only the upregulation of cAFF1 was found to be independent of hypoxia-induced transcriptional changes ( Figure  3E and 3F).
cZNF292 Regulates Angiogenic Sprouting
With respect to circRNAs, one of the key questions is whether these transcripts have biological functions or are mere byproducts of mRNA processing. To address this question, we focused on cZNF292, which was among the highest expressed and significantly hypoxia-regulated circRNAs, and confirmed its expression by Northern blot (Online Figure   Figure 3 IV). Using RNase R-treated RNA, we cloned cZNF292 by using primers directly flanking the predicted back-splice site and confirmed the circularization of exon 4 to intron 1 ( Figure 4A ; Online Figure V) . A detailed analysis uncovered an alternative exon 1A located in intron 1 of which the 5′ end functions as splice acceptor site during back-splicing. Next, we silenced cZNF292 by using 2 siRNAs directed against exon 1A ( Figure 4B ) since the sequence of the backsplice site was not suitable for the generation of specific siRNAs (because of potential off target effects and high GC [guanine and cytosine base pairs] content). We confirmed that both siRNAs silenced cZNF292 but did not affect premRNA levels or ZNF292 protein expression (Online Figure  VI) . siRNA-mediated silencing of cZNF292 significantly inhibited spheroid sprouting ( Figure 4C ), tube formation in matrigel assays (Online Figure VII) , and reduced endothelial cell proliferation ( Figure 4D ). Transfection of a plasmid that was designed to generate the circular transcript of ZNF292 enhanced proliferation, whereas overexpression of linear exon 1A to 4 did not affect cell-cycle progression (Online Figure VIII) .
Having demonstrated that cZNF292 regulates angiogenic sprouting, we aimed to obtain insights into its mechanism. Although nuclear circRNAs may interfere with the generation of their host gene, 6 siRNA-mediated silencing of cZNF292 did not affect ZNF292 mRNA expression ( Figure 4E ). Because circRNAs were shown to act as sponges for microRNAs (miRNAs), we determined whether this mechanism may also account for cZNF292. By merging our identified circRNAs with the published high-throughput sequencing of RNA isolated by cross-linking and immunoprecipitation (HITS-CLIP) data from HUVEC 15 (experimentally determined binding sites of Ago proteins), we bioinformatically characterized putative miRNA-binding sites within endothelial circRNAs ( Figure  4F ; Online Table IV) . However, no HITS-CLIP peaks were detected for cZNF292 indicating that cZNF292 does not associate with Argonaute, making a potential function as miRNA sponge unlikely. 
Discussion
This study confirms that circRNAs are abundantly expressed in endothelial cells. Many of the identified circRNAs have already been described and annotated by others. [3] [4] [5] 10 Among the highest expressed circRNAs, cEphB4 was recently identified and characterized in other cell types. 16 Besides identifying back-splicing events based on the usage of constitutive splice sites, we additionally demonstrate the usage of alternative 3′ splice sites (eg, cZNF292). Furthermore, we characterized hypoxia-controlled endothelial circRNAs and showed that one of the highly expressed and significantly regulated circRNAs, cZNF292, exhibits biological functions in endothelial cells. Selective depletion of cZNF292 by 2 different siRNAs inhibits angiogenic sprouting of endothelial cells, suggesting that cZNF292 exhibits a proangiogenic function. The proproliferative effect of cZNF292 was further confirmed by overexpression of cZNF292.
Little is known about the function of the zinc finger domain-containing transcription factor ZNF292 in the cardiovascular system: ZNF292 is expressed at a biologically meaningful level (fragments per kilobase of transcript per million mapped reads ≈10) in endothelial cells, but its regulation has only been described in hematopoietic cells. 17 Furthermore, the mechanism by which cZNF292 controls angiogenic functions is unclear. Our results argue against a recently described cis-regulatory function of circular intronic transcripts on host gene expression 6 because siRNAmediated silencing of cZNF292 did not affect expression of ZNF292 mRNA. The lack of cis-regulatory activity is also consistent with a predominant cytoplasmic localization of cZNF292 raising the possibility that cZNF292 may act as miRNA sponge rather than regulating host gene expression. However, there was no evidence for Argonaute binding to cZNF292 from HITS-CLIP data, suggesting that a putative function as an miRNA sponge, at least under unstimulated conditions, is unlikely. Moreover, for the top 30 expressed circRNAs, predicted miRNA-binding sites were only verified in Argonaute HITS-CLIP data for cHIPK3 and cCRIM1 (Online Tables V and VI) suggesting that most endothelialenriched circRNAs do not act as miRNA sponges. A recent study demonstrated that circular viroid RNAs can exhibit coding potential. 18 The presence of internal ribosomal entry sites might allow formation of peptides or proteins from circular RNA. Thus, in vitro translation studies are necessary to experimentally address this potential function of cZNF292.
The mechanism by which circularization is affected by hypoxia also deserves further exploration: whereas under basal conditions levels of circRNAs and host gene expression did not significantly correlate ( Figure 1C ), hypoxia-induced changes of host gene levels were found to be reflected in most of the selected circRNAs. In the case of cZNF292, we demonstrate that hypoxia-induced upregulation is not mediated by the hypoxiainduced transcription factor 1a (Online Figure IX) , but further studies are required to elucidate whether this is true for other circRNA transcripts. Because no correlation between circRNA and mRNA expression was observed when all transcripts were included into the analysis (Online Figure X) What Is Known?
• Over 70% of the human genome is transcribed, but merely 3% is translated into proteins.
• Several classes of noncoding RNAs have been shown to be involved in the regulation of physiological and pathophysiological processes.
• Circular RNAs are widely expressed among cells and tissues and are mainly generated from back-spliced exons of protein coding genes.
What New Information Does This Article Contribute?
• Circular RNAs are expressed in endothelial cells and are regulated by hypoxia.
• The circular RNA cZNF292 controls proliferation and angiogenic sprouting in endothelial cells.
Next generation sequencing revealed >70% of the human genome is transcribed giving rise to several classes of noncoding RNAs. Of those, circular RNAs are generated from back-spliced exons or introns mainly of protein-coding genes. In our study, we found 7388 circular RNAs expressed in endothelial cells and biochemically validated 7 candidates. Several circRNAs were significantly regulated by hypoxia, which is a key stimulus for angiogenesis. Circular ZNF292 was found to be regulated by hypoxia and involved in the regulation of proliferation and angiogenic sprouting in endothelial cells.
1
ONLINE SUPPLEMENTAL MATERIAL ONLINE MATERIAL & METHODS
Cell culture
Endothelial cells were purchased from Lonza and cultured as previously described 1 under hypoxic (0.2% O 2 ) or normoxic conditions (3.5*10 4 /cm²). For hypoxia with different cell densities, HUVECs were seeded in a 60 mm dish with low (6.6*10 3 /cm²) and high (6.6*10 4 /cm²) density. For CoCl 2 treatment, 4*10 5 HUVECs were seeded in 60 mm cell culture dishes. HEK-293T cells were cultured in DMEM containing 10% FCS, 100 U/ml penicillin and 0.1 mg/ml streptomycin.
RNA isolation and sequencing RNA was isolated using Qiazol (79306; Qiagen) and miRNeasy-Kit (217004; Qiagen) with additional DNase I (79254; Qiagen) digestion according to the manufacturer's protocol. 0.5 μg rRNA-depleted RNA was fragmented and primed for cDNA synthesis. The sequencing libraries were constructed using Illumina® TruSeq™ RNA Sample Preparation Kits and were sequenced by Illumina HiSeq™ 2000 flowcell.
Computational analysis of RNA/miR-seq and circRNAs
The rRNA-depleted RNA-seq data were analyzed using the circBase pipeline 2 with default settings using an anchor length of 20 bp. The circBase pipeline finds potential circRNAs from reads that were not mapped to the reference genome. Results were filtered for circRNAs having at least two unique reads, a mapping quality greater than 35 for both anchor sequences, and a length shorter than 100,000 bp. The existence of the predicted circRNAs was verified by searching the raw sequencing data with 80bp of the back-spliced sequences. To annotate the identified circRNAs in HUVEC, HOMER 3 was used. For the identification of potential miR binding sites, Ago1-4 HITS-CLIP experiments of HUVEC 4 were downloaded from the Gene Expression Omnibus (GSE41272) as BED files. Since the original data analysis was performed to the human genome hg18, the BED file was converted to hg19 using CrossMap (http://crossmap.sourceforge.net). Next, the identified circRNAs were compared with the HITS-CLIP data using BEDTools 5 , which resulted in the identification of 713 overlapped sites from 6,046 HITS-CLIP peaks. To predict potential miR binding sites, miRanda 6 was used. For the analysis of miR-seq data, the pipeline of CAP-miRSeq was used with the default parameters 7 . Total reads per sample are given in the 
RNase R digestion
For RNase R digestion, 6 µg RNA were incubated with 6 U RNase R (RNR-07250, epicentre) in 1x RNase R buffer in a 20 µl reaction at 37°C for 10 min followed by heat inactivation at 95°C for 3 min. Control samples were treated the same way but lacked RNase R digestion.
Preparation of poly-A +/-RNA RNA was fractionated into RNA with and without poly-A tail by using 100 µl oligo-d(T)
25
-Magnetic Beads (S14195, NEB) per 6 µg RNA. To this end, beads were washed with washing buffer (300 mM NaCl, 20 mM Tris-HCl, 0.01% NP-40) prior to oligo-d(T) selection. RNA was incubated with beads in an appropriate amount of 2x binding buffer (300 mM NaCl, 40 mM Tris-HCl, 0.02% NP-40) for 10 minutes with rotation. For separation, tubes were placed on a magnet and the supernatant containing the oligo-d(T) 25 negative RNA was collected. Beads were washed three times with washing buffer and were incubated afterwards at 50°C in elution buffer (150 mM NaCl, 20 mM Tris-HCl, 0.01% NP-40) for 2 min to elute poly-adenylated RNAs.
cDNA synthesis 1 or 6 µg RNA were reverse transcribed by MuLV reverse transcriptase (N808-0018, Invitrogen) in a total volume of 40 µl. Reverse transcription was primed by random hexamers (N8080127, Invitrogen). Synthesized cDNA was diluted 1:5 prior to PCR. PCR circRNAs, mRNAs or pre-mRNAs were amplified using RT-PCR or qRT-PCR as indicated in the figure legends. For RT-PCR, 5 µl 1:5 diluted cDNA was amplified (22-37cycles, depending on the template) in a 25 µl PCR reaction using the KOD Xtreme TM HotStart Polymerase Kit (71975-3, Novagen). For qRT-PCR, cDNA was amplified using fast Fast Sybr Green Mastermix (Life Technologies, #4385612) on a VIAA7 qPCR System (Life Technologies). Expression level of circRNAs, mRNAs or pre-mRNAs were normalized to the housekeeping gene RPLP0 by using the 2 -ΔCt method for qRT-PCR measurements or by calculating ratios based on densitometry for semi-quantitative RT-PCRs. Full-length cZNF292 (Including all exons from exon 1A to exon 4) was amplified by RT-PCR on RNase R-treated samples, using primers directly flanking the back-splice site. PCR products were cloned using HindIII and XhoI restriction sites. Clones were sequenced and used for subcloning into pcDNA3.1 (+) in order to generate a vector suitable for overexpression of cZNF292. To this end, the In-Fusion® HD Cloning Plus Kit (638910, Takara Clontech) was used to insert four fragments into the KpnI-linearized vector backbone, covering 50 nt up-and downstream of exons 1A and 4, respectively, cZNF292, as well as flanking sequences of 220 nt, derived from intron 1 in sense and antisense orientation. Plasmid encoding linear ZNF292 (exons 1A to 4), was generated by cloning fragment 2 in pcDNA3.
PCR primers
Primer name Sequence (5'->3') Product size (bp)
Primer sequences for In-Fusion cloning of cZNF292
Name Sequence 5'->3' 
Spheroid sprouting assays
Spheroid assays were performed as previously described 8 . In vitro angiogenesis was quantified by measuring the cumulative length of all sprouts of each spheroid or the maximal distance of the migrated cells ("sprout outgrowth length") using digital imaging analysis software (AxioVision Rel. 4.8, Carl Zeiss). 10-12 spheroids were analyzed for each experiment.
Endothelial network-formation assay 3.5*10 5 HUVECs were seeded in a 60 mm cell culture dish. After 24 h, siRNAs targeting cZNF292 were transfected at a final concentration of 67 nM using RNAiMax transfection reagent. After additional 24 h, 7.5*10 4 transfected cells were seeded onto matrigel in a 6-well for 24 h. Then, network-formation was analyzed by measuring the cumulative length in 5 random fields.
Proliferation
Cell cycle analysis was performed using the FITC BrdU Flow Kit (557891, BD Pharmigen). To this end, 3*10 5 HUVECs or HEK cells were seeded in a 60 mm cell culture dish and transfected 24 h later as described above. 24 h after transfection BrdU was added to a final concentration of 10 nM to the culture media for 30 min. Cells were harvested by trypsinization and washed with PBS. Fixation and BrdU staining was performed following manufacturer's instructions. BrdU staining was achieved with V450 mouse anti-BrdU antibody (560810, BD Pharmigen). Analysis was conducted by flow cytometry.
Northern blot PCR primers including T7 promoter sequences were designed to target the linear and circular transcript of ZNF292 simultaneously, linear GADPH, or the circular ZNF292 transcript exclusively (ZNF292: 190 bp; GAPDH: 300 bp; cZNF292: 224 bp).
Primer sequences for Northern blot probe
Name
Sequence 5'->3' (T7 promoter in red)
In vitro transcription using 5 µg unpurified PCR-template was performed using DIG RNA Labeling Kit (Roche; 11175025910) including subsequent DNase I digestion of the template according to the manufacturer's instruction. The DIG-probe was purified using Qiazol (79306; Qiagen) and precipitated with isopropanol with additional ethanol washing.
HEK or HUVEC RNA was mixed with Northern Max-Gly sample loading dye (LifeTech; AM8551) and loaded onto 1.2% agarose gel in MOPS buffer (Ambion; 8671G). Subsequently, the gel was equilibrated in 1X TBE for 20 min and RNA was electroblotted onto nylon membranes (Roche; 11209299001) using a Thermo Pierce G2 Fast Blotter device (15V, 1A, 1h). Subsequently, membranes were UV cross-linked and prehybridized in Ultra Hyp hybridization buffer (Life technologies; AM8670) at 68°C for 30 min. For hybridization, the membranes were then incubated with 50 ng/ml DIGlabelled RNA antisense probe in Ultra Hyp hybridization buffer (Life technologies; AM8670) at 68°C overnight in a wet chamber. After washing (one time for 30 min with 2x SSC, 1% SDS followed by two times for 15 min with 2x SSC 0.1% SDS) the membranes were blocked and detection was done using DIG luminescent Detection kit (Roche; 11363514910) according to manufacturer's instructions. For detection of GAPDH, membranes were stripped with 2x SSC (1% SDS) for 30 min at 60°C followed by 2x 15 min with 2x SSC (0.1% SDS) at room temperature and probed with DIG-labelled GAPDH probes as described above.
Immunoblot
HUVECs were seeded in a 60 mm cell culture dish 24 h prior to transfection with 60 nM of siRNAs (Sigma) using the GeneTrans II (0203B, Mobitec) transfection reagent, following the manufacturer's protocol. 24 h after siRNA transfection, total cell lysate and was prepared and 30 µg/lane were separated by SDS-page, blotted on nitrocellulose membranes, blocked (3% milk in TBS-T) and incubated with antibodies targeting ZNF292 (ab111438 Abcam; 1:500) or beta-actin (ab3280 Abcam; 1:400). A, 20 µg HUVEC RNA was loaded onto 1.2% agarose gel, transferred to nylon membrane and then incubated with 50 ng/ml dig-labelled RNA antisense probe spanning exon 3 and 4, which is expressed in the linear and circular ZNF292 transcript, in hybridization buffer at 68°C overnight in a wet chamber. The linear tanscript is expressed at lower levels and is hardly detectable. The membrane was stripped and reprobed with a probe specifically detecting the back-splice site (right panel).
To evaluate band sizes, a DNA marker was used (#SM1173; Fermentas). B, 24 h after transfection of HUVEC with siRNAs directed against cZNF292, 10 µg RNA were loaded on a gel, blotted and membranes were incubated with 50 ng/ml dig-labelled RNA antisense probe spanning exon 3 and 4 and reprobed with a 50 ng/ml dig-labelled RNA antisense probe that detects GAPDH mRNA as a loading control. HUVECs were seeded in 60 mm cell culture dishes. After 24 h, siRNAs targeting cZNF292 were transfected at a final concentration of 60 nM using GeneTransII transfection reagent. After 24 h, pre-mRNA levels of ZNF292 were analyzed by qPCR (normalized to RPLP0) using the primer pairs indicated in panel A (all n=3). E, Immunoblot of ZNF292 protein levels after siRNA-mediated knockdown of cZN292 (n=4). 
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